Chugai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chugai Pharmaceutical Co., Ltd.
The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Chugai Pharma Europe
- Chugai Pharma Taiwan Ltd.
- C&C Research Laboratories